title: Pemetrexed in previously treated non-small-cell lung cancer.
abstract: Several decades of chemotherapy trials in non-small-cell lung cancer (NSCLC) have clearly shown a survival benefit for chemotherapy over best supportive care. However, only short-lived responses are attained, with an average of four cycles of chemotherapy, before tumor progression is observed. Second-line chemotherapy has been demonstrated to improve outcome, with docetaxel (Taxotere) as the predominant cytotoxic drug. A recent randomized trial in second-line NSCLC indicated that the novel drug pemetrexed (Alimta) attained the same response, time to progression, and survival as docetaxel. This finding ushers in a new age in second-line treatment that can be further invigorated by the addition of targeted agents. Accumulated evidence indicates that overexpression of epidermal growth factor receptor and HER2/neu, which occurs frequently in NSCLC, leads to the deregulation of PI3K and MAPK, activating Akt and enhancing chemoresistance. Future clinical trials in NSCLC will include tailored and multitargeted therapy and pemetrexed represents a significant step forward in this direction.
authors.affiliation: Medical Oncology Service, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona (Barcelona), Spain. rrosell@ns.hugtip.scs.es
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
authors.forename: Jose Miguel
authors.initials: JM
authors.lastname: Sanchez
authors.forename: Miquel
authors.initials: M
authors.lastname: Taron
authors.forename: Teresa
authors.initials: T
authors.lastname: Moran
authors.forename: Beatriz
authors.initials: B
authors.lastname: Ciuraqui
authors.forename: Mercedes
authors.initials: M
authors.lastname: Canela
authors.forename: Enriqueta
authors.initials: E
authors.lastname: Felip
authors.forename: Bartomeu
authors.initials: B
authors.lastname: Massuti
authors.forename: Carlos
authors.initials: C
authors.lastname: Camps
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D000068437:Pemetrexed; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
chemical_list: D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D013940:Thymidylate Synthase